Confo Therapeutics Archives

Home Confo Therapeutics

Latest Posts

News and Trends 3 Mar 2023

Lilly to develop Confo pain drug

Confo Therapeutics, which works on the discovery of medicines targeting G-protein coupled receptors (GPCRs), has announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds. CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R) is currently in phase 1 clinical development. It represents a […]

March 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 May 2019

Belgian Biotech Raises €30M Series A to Unlock Undruggable Targets

Confo Therapeutics has raised €30M in a Series A round that will take its unique technology to find drugs for historically undruggable targets to clinical trials. The fundraising was led by the VCs BioGeneration Ventures and Wellington Partners, and joined by several other private and public investors. With the money, Confo Therapeutics aims to […]

May 7, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Dec 2017

Belgian Biotech and Roche Take on Neurological and Developmental Disorders

Confo Therapeutics has joined forces with Roche to develop new small molecule agonists of a G-protein coupled receptor to treat neurological and developmental disorders. Confo Therapeutics is developing a pipeline of G-protein coupled receptor (GPCR)-targeting drugs to address an unmet medical needs. The biotech spun out from the Vrije Universiteit Brussel in 2015 with the backing of […]

December 19, 2017 - 2 minutesmins - By Alex Dale

News and Trends 26 Sep 2017

Belgian Biotech Teams Up With Lundbeck to Collaborate on Drug Discovery

Confo and Lundbeck have joined forces to push through drug discovery against a tough-to-target protein using Confo’s special technology. Confo Therapeutics develops small antibody fragments, ‘Confobodies’, that stabilize G-protein coupled receptors (GPCRs). Although Lundbeck has the exclusive license to commercialize compounds from the collaboration, Confo would receive up to €5M in technology fees, plus milestone payments and royalties depending on […]

September 26, 2017 - 2 minutesmins - By Alex Dale

News and Trends 1 Feb 2017

Young Belgian Biotech will tackle Fibrosis with a New Grant

Confo Therapeutics has received a €1.6M grant to support the discovery of drugs against fibrosis, one of the most deadly conditions in Western countries. Confo Therapeutics is a young biotech in Brussels developing a unique technology to target historically undruggable G protein-coupled receptors (GPCRs). The company just announced it received a €1.6M grant from Flanders Innovation & […]

February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Nov 2016

These Biotech Veterans have Launched a Startup to ‘Drug the Undruggable’

GPCRs have spelled “dead end” for many a biotech and academic endeavor. I sat down with Confo Therapeutics to hear about how they’re recruiting antibodies for a new onslaught. Despite their allure as the key to many indications, GPCRs are not a target for the faint of heart because they tend to move through a […]

November 23, 2016 - 4 minutesmins - By Evelyn Warner

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us